Write your message
Volume 1, Issue 2 (9-2016)                   J Obstet Gynecol Cancer Res 2016, 1(2): 0-0 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Ansarinejad N, Abbasi B, Sadat Rasul M S, Fardad F, Ramim T. The Effectiveness of Ferric Carboxymaltose on the Improvement of Chronic Iron Deficiency Anemia in Patients With Colon Cancer: A Controlled Randomized Clinical Trial. J Obstet Gynecol Cancer Res. 2016; 1 (2)
URL: http://jogcr.com/article-1-116-en.html
1- Department of Hematology and Oncology, Hazrat Rasool-e Akram Hospital, Iran University of Medical Sciences, Tehran, IR Iran
2- Cancer Pharmacogenetics Research Group (CPGRG), Iran University of Medical Sciences, Tehran, IR Iran
3- Hospital Pharmacy Management, Iran University Medical Sciences, Tehran, IR Iran
4- Cancer Pharmacogenetics Research Group (CPGRG), Iran University of Medical Sciences, Tehran, IR Iran , tayebramim@yahoo.com
Abstract:   (1849 Views)
Background: Anemia is prevalent in 32% to 60% of patients with cancer due to an underlying disease, nutritional deficiencies and complications of medication used in chemotherapy. National Comprehensive Cancer Network (NCCN) recommends the use of oral or intravenous iron supplementation in patients with iron deficiency anemia.
Full-Text [PDF 179 kb]   (1216 Downloads)    
Systematic Review: Original Research | Subject: Obstetrics and Gynecology
Received: 2018/05/4 | Accepted: 2018/12/29 | Published: 2018/12/29

References
1. World Health Organization . Iron deficiency anemia: assessment. Prevention And Control.; 2001.
2. Arora NP, Ghali JK. Iron deficiency anemia in heart failure. Heart Fail Rev. 2013;18(4):485-501. doi: 10.1007/s10741-012-9342-y. [DOI:10.1007/s10741-012-9342-y]
3. Goddard AF, James MW, McIntyre AS, Scott BB, British Society of G. Guidelines for the management of iron deficiency anaemia. Gut. 2011;60(10):1309-16. doi: 10.1136/gut.2010.228874. [DOI:10.1136/gut.2010.228874]
4. Breymann C, Bian XM, Blanco-Capito LR, Chong C, Mahmud G, Rehman R. Expert recommendations for the diagnosis and treatment of iron-deficiency anemia during pregnancy and the postpartum period in the Asia-Pacific region. J Perinat Med. 2011;39(2):113-21. [DOI:10.1515/jpm.2010.132]
5. Goodnough LT. Iron deficiency syndromes and iron-restricted erythropoiesis (CME). Transfusion. 2012;52(7):1584-92. [DOI:10.1111/j.1537-2995.2011.03495.x]
6. Obrand DI, Gordon PH. Incidence and patterns of recurrence following curative resection for colorectal carcinoma. Dis Colon Rectum. 1997;40(1):15-24. [DOI:10.1007/BF02055676]
7. Ganz T. Systemic iron homeostasis. Physiol Rev. 2013;93(4):1721-41. [DOI:10.1152/physrev.00008.2013]
8. Hedenus M, Karlsson T, Ludwig H, Rzychon B, Felder M, Roubert B, et al. Intravenous iron alone resolves anemia in patients with functional iron deficiency and lymphoid malignancies undergoing chemotherapy. Med Oncol. 2014;31(12):302. [DOI:10.1007/s12032-014-0302-3]
9. Geisser P. The pharmacology and safety profile of ferric carboxymaltose (Ferinject): structure/reactivity relationships of iron preparation. Port J Nephrol Hypert. 2009;23(1):11-6.
10. Funk F, Ryle P, Canclini C, Neiser S, Geisser P. The new generation of intravenous iron: chemistry, pharmacology, and toxicology of ferric carboxymaltose. Arzneimittelforschung. 2010;60(6a):345-53. [DOI:10.1055/s-0031-1296299]
11. Geisser P, Rumyantsev V. Pharmacodynamics and safety of ferric carboxymaltose: a multiple-dose study in patients with iron deficiency anaemia secondary to a gastrointestinal disorder. Arzneimittelforschung. 2010;60(6a):373-85. [DOI:10.1055/s-0031-1296302]
12. Geisser P, Banke-Bochita J. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia. Arzneimittelforschung. 2010;60(6a):362-72. [DOI:10.1055/s-0031-1296301]
13. Bisbe E, Molto L, Arroyo R, Muniesa JM, Tejero M. Randomized trial comparing ferric carboxymaltose vs oral ferrous glycine sulphate for postoperative anaemia after total knee arthroplasty. Br J Anaesth. 2014;113(3):402-9. [DOI:10.1093/bja/aeu092]
14. National Comprehensive Cancer Network . clinical practice guidelines in oncology (NCCN guidelines). Cancer and chemotheraphy induced anemia 2015. [cited 6 Nov]. Available from: http://www.nccn.org.
15. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361(25):2436-48. [DOI:10.1056/NEJMoa0908355]
16. Borstlap WA, Buskens CJ, Tytgat KM, Tuynman JB, Consten EC, Tolboom RC, et al. Multicentre randomized controlled trial comparing ferric(III)carboxymaltose infusion with oral iron supplementation in the treatment of preoperative anaemia in colorectal cancer patients. BMC Surg. 2015;15:78. https://doi.org/10.1186/s12893-015-0065-6 [DOI:10.1186/s12893-015-0090-5]
17. Steinmetz T, Tschechne B, Harlin O, Klement B, Franzem M, Wamhoff J, et al. Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. Ann Oncol. 2013;24(2):475-82. doi: 10.1093/annonc/mds338. [DOI:10.1093/annonc/mds338]
18. Toledano A, Luporsi E, Morere JF, Scotte F, Huot-Marchand P, Zakin L, et al. Observational study of ferric carboxymaltose (FCM) in france (oncofer study; interim analysis). Value Health. 2013;16(3):A112. [DOI:10.1016/j.jval.2013.03.537]
19. Athibovonsuk P, Manchana T, Sirisabya N. Prevention of blood transfusion with intravenous iron in gynecologic cancer patients receiving platinum-based chemotherapy. Gynecol Oncol. 2013;131(3):679-82. [DOI:10.1016/j.ygyno.2013.09.028]

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License Journal of Obstetrics, Gynecology and Cancer Research by Farname Inc is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. Based on a work at http://jogcr.com/.

© 2022 CC BY-NC 4.0 | Journal of Obstetrics, Gynecology and Cancer Research (JOGCR)

Designed & Developed by : Yektaweb | Piblisher: Farname Inc.